For research purposes only

Cat. No BA93604049

Availability - up to 100 mg in stock
- larger amount can be synthesized in 8 weeks

Description of biological activity

Inhibitor of Fatty Acid Amide Hydrolase (FAAH) The compound inhibits Fatty Acid Amide Hydrolase (FAAH) with Ki 0.0047 μM. The enzyme assays were performed at 20-23 °C with purified recombinant rat FAAH expressed in E. coli in a 125 mM Tris/1 mM EDTA/0.2% glycerol/0.02% Triton X-100/0.4 mM Hepes, pH 9.0 buffer. The initial rates of hydrolysis (≤10-20% reaction) were monitored using enzyme concentrations at least 3 times below the measured Ki by following the breakdown of 14C-oleamide [1]. The compound showed analgesia effect in different animal models [J. Pharm. Exp. Ther. 2004, 311, 441-448].

Keywords: Analgesic


1-oxo-1-[5-(phenyl)oxazol-2-yl]-7-phenylheptane inhibitor of Fatty Acid Amide Hydrolase (FAAH)

IUPAC Name: 1-oxo-1-[5-(phenyl)oxazol-2-yl]-7-phenylheptane

CAS Number: 681135-77-3

Purity: > 96% chemical purity (LCMS)


1. J.Med.Chem. 2005, 48, 1849-1856
2. Brit. J. Pharmacol., 2006, 148, 102-113

Latest added compounds


Selective inhibitor of MCT1 with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. Both lactate transport and cell growth are potently inhibited.




selective inhibitor of Nav1.8 sodium channel (IC50 = 3 nM); for TRPV1, P2X2/3, Cav2.2 calcium channels, KCNQ2/3 potassium channels IC50 >10 µM




inhibitor of ubiquitin ligase Smad ubiquitination regulatory factor-1 (Smuf1)

Bone disorders